NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) — via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) declared that it has been included in an editorial published by BioMedWire (BMW). BMW is among over 75 brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform concentrating on financial news and content distribution for private and public companies and the investment community.
The full publication, “Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development,” is accessible at: https://ibn.fm/7N5vp
Biotechnology mergers and acquisitions (M&As) are now being directed by a evident strategic shift. Pharmaceutical corporations are favoring clinical-stage and late-stage initiatives supported by human data instead of early discovery platforms with indeterminate schedules. Subsequent to a period where capital was heavily allocated to preclinical innovation, investors and acquirers are currently targeting assets that display safety signals, efficacy data, and more distinct pathways to commercialization.
Within this changing scenario, enterprises with diversified clinical-stage portfolios across oncology and central nervous system (CNS) indications are receiving renewed focus. A case in point is Oncotelic Therapeutics Inc., which recently reported expanded international intellectual property protection for OT-101, its proprietary TGF-β antisense therapeutic platform. This advancement enhances safeguards in neurology, oncology, and CNS drug-delivery technologies intended to cross the blood–brain barrier.
About Oncotelic Therapeutics Inc.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical firm committed to developing oncology and immunotherapy products. Its mission is to tackle cancers with high unmet needs and rare pediatric indications using innovative, late-stage therapeutic candidates. Besides its directly owned and developed drug pipeline, Oncotelic advantages from the extensive invention portfolio created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. the company licenses and co-develops certain drug candidates via joint ventures. Currently, Oncotelic possesses 45% of GMP Bio, a joint venture under Trieu’s leadership and direction, which is advancing its own pipeline of drug candidates that further complement and reinforce Oncotelic’s strategic position in oncology and rare disease therapeutics.